Literature DB >> 19276374

Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells.

Nader Rahimi1, Todd E Golde, Rosana D Meyer.   

Abstract

Vascular endothelial growth factor receptor-1/fms-related tyrosine kinase 1 (VEGFR-1/FLT1) is expressed as a membrane-bound receptor tyrosine kinase and as an alternatively spliced soluble protein (sVEGFR-1) containing the 1-6 IgG-like domain of its ectodomain. sVEGFR-1 is known as a naturally occurring inhibitor of angiogenesis and as a surrogate marker for cancer progression; it is also linked to pregnancy-induced hypertension called preeclampsia and to avascularity of normal cornea. It remains an open question whether alternative mRNA splicing is the only mechanism by which sVEGFR-1 is generated. In this study, we show that in leukemic cancer cells, PlGF and VEGF-A both induce tyrosine phosphorylation of VEGFR-1 and render it susceptible to ectodomain shedding, resulting in the generation of sVEGFR-1 and an intracellular cytoplasmic fragment. Activation of protein kinase C and tumor necrosis factor-alpha-converting enzyme family metalloproteases are critically required for the occurrence of sVEGFR-1. Following the removal of the ectodomain, the remnant of VEGFR-1 remains attached to the membrane, and the activity of gamma-secretase/presenilin is required for its release from the cell membrane. We propose that sVEGFR-1 produced via ectodomain shedding plays a prominent role in the VEGF receptor system by antagonizing VEGF receptor signaling by acting as a dominant-negative form and/or forming a nonsignaling dimerizing complex with VEGF receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276374      PMCID: PMC2674781          DOI: 10.1158/0008-5472.CAN-08-2905

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

Review 1.  Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides.

Authors:  Andreas Weihofen; Bruno Martoglio
Journal:  Trends Cell Biol       Date:  2003-02       Impact factor: 20.808

2.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.

Authors:  R L Kendall; K A Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

3.  Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors.

Authors:  Suya Yang; Karen Toy; Gladys Ingle; Constance Zlot; P Mickey Williams; Germaine Fuh; Bing Li; Abraham de Vos; Mary E Gerritsen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-11-01       Impact factor: 8.311

4.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium.

Authors:  G H Fong; J Rossant; M Gertsenstein; M L Breitman
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

5.  Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.

Authors:  Agnieszka Wierzbowska; Tadeusz Robak; Agata Wrzesień-Kuś; Anna Krawczyńska; Ewa Lech-Marańda; Halina Urbańska-Ryś
Journal:  Eur Cytokine Netw       Date:  2003 Jul-Sep       Impact factor: 2.737

6.  Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta 1 integrin.

Authors:  Angela Orecchia; Pedro Miguel Lacal; Cataldo Schietroma; Veronica Morea; Giovanna Zambruno; Cristina Maria Failla
Journal:  J Cell Sci       Date:  2003-07-15       Impact factor: 5.285

7.  Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Qinglong Hu; Amanda L Dey; Ying Yang; Yu Shen; Iman B Jilani; Elihu H Estey; Hagop M Kantarjian; Francis J Giles; Maher Albitar
Journal:  Cancer       Date:  2004-05-01       Impact factor: 6.860

8.  Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo.

Authors:  Eunice S Wang; Julie Teruya-Feldstein; Yan Wu; Zhenping Zhu; Daniel J Hicklin; Malcolm A S Moore
Journal:  Blood       Date:  2004-07-06       Impact factor: 22.113

9.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.

Authors:  J Waltenberger; L Claesson-Welsh; A Siegbahn; M Shibuya; C H Heldin
Journal:  J Biol Chem       Date:  1994-10-28       Impact factor: 5.157

10.  The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.

Authors:  C de Vries; J A Escobedo; H Ueno; K Houck; N Ferrara; L T Williams
Journal:  Science       Date:  1992-02-21       Impact factor: 47.728

View more
  42 in total

1.  The cytosolic domain of protein-tyrosine kinase 7 (PTK7), generated from sequential cleavage by a disintegrin and metalloprotease 17 (ADAM17) and γ-secretase, enhances cell proliferation and migration in colon cancer cells.

Authors:  Hye-Won Na; Won-Sik Shin; Andreas Ludwig; Seung-Taek Lee
Journal:  J Biol Chem       Date:  2012-06-04       Impact factor: 5.157

Review 2.  Molecular Mechanisms of Preeclampsia.

Authors:  Tammy Hod; Ana Sofia Cerdeira; S Ananth Karumanchi
Journal:  Cold Spring Harb Perspect Med       Date:  2015-08-20       Impact factor: 6.915

Review 3.  Receptor tyrosine kinases in the nucleus.

Authors:  Graham Carpenter; Hong-Jun Liao
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-10-01       Impact factor: 10.005

4.  Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1.

Authors:  C Li; N S Raikwar; M K Santillan; D A Santillan; C P Thomas
Journal:  Placenta       Date:  2015-01-17       Impact factor: 3.481

Review 5.  Angiogenic factors in preeclampsia and related disorders.

Authors:  Ana Sofia Cerdeira; S Ananth Karumanchi
Journal:  Cold Spring Harb Perspect Med       Date:  2012-11-01       Impact factor: 6.915

6.  Ectodomain cleavage of FLT1 regulates receptor activation and function and is not required for its downstream intracellular cleavage.

Authors:  Nandita S Raikwar; Kang Z Liu; Christie P Thomas
Journal:  Exp Cell Res       Date:  2016-03-23       Impact factor: 3.905

7.  Circulating ADAM17 Level Reflects Disease Activity in Proteinase-3 ANCA-Associated Vasculitis.

Authors:  Anna Bertram; Svjetlana Lovric; Alissa Engel; Michaela Beese; Kristin Wyss; Barbara Hertel; Joon-Keun Park; Jan U Becker; Johanna Kegel; Hermann Haller; Marion Haubitz; Torsten Kirsch
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

Review 8.  Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer.

Authors:  Miles A Miller; Ryan J Sullivan; Douglas A Lauffenburger
Journal:  Clin Cancer Res       Date:  2016-11-28       Impact factor: 12.531

9.  Vascular Endothelial Growth Factor Receptor 1 morpholino increases graft survival in a murine penetrating keratoplasty model.

Authors:  Yang Kyung Cho; Xiaohui Zhang; Hironori Uehara; Jason R Young; Bonnie Archer; Balamurali Ambati
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-12-19       Impact factor: 4.799

10.  Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport.

Authors:  Florence T H Wu; Marianne O Stefanini; Feilim Mac Gabhann; Christopher D Kontos; Brian H Annex; Aleksander S Popel
Journal:  Physiol Genomics       Date:  2009-04-07       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.